Posted by Michael Wonder on 06 Oct 2017
EMA takes yet another step in public engagement with its first public hearing
6 October 2017 - Summary report now published.
Patients, carers, doctors, pharmacists and academia shared their experience with valproate - a medicine that treats epilepsy, bipolar disorder and migraine - at the first public hearing held by the EMA at its offices in London on 26 September 2017.
“The European Parliament insisted on including public hearings in the EU law on medicines safety,” said Linda McAvan, Member of the European Parliament. “The positive experience from EMA’s first public hearing confirms that giving patients a platform to tell their story was the right thing to do.”
